RT Journal Article
SR Electronic
T1 Best Practices for <sup>18</sup>F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 282
OP 287
DO 10.2967/jnmt.119.227116
VO 47
IS 4
A1 Funmilayo I. Tade
A1 Rebecca A. Sajdak
A1 Mehdat Gabriel
A1 Robert H. Wagner
A1 Bital Savir-Baruch
YR 2019
UL http://tech.snmjournals.org/content/47/4/282.abstract
AB 18F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. 18F-fluciclovine PET/CT is performed significantly differently from 18F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the 18F-fluciclovine PET/CT protocol.